Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Daniel J. Lee et al.|The Lancet Neurology|2023Cited by 128
A mutation rate model at the basepair resolution identifies the mutagenic effect of polymerase III transcriptionVladimir B. Seplyarskiy, Shamil Sunyaev, Evan Koch et al.|Nature Genetics|2023Cited by 55
A mutation rate model at the basepair resolution identifies the mutagenic effect of Polymerase III transcriptionVladimir B. Seplyarskiy, Shamil Sunyaev, Harding H. Luan et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 10